G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020

NEXT STORY
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
PREV STORY
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

author_avatar
NASDAQ Market News

RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017

TEL-AVIV, Israel, May 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...

author_avatar
NASDAQ Market News

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

author_avatar
NASDAQ Market News